227 related articles for article (PubMed ID: 9727319)
1. [Changes in the levels of prostate-specific antigen and its molecular forms with alpha 1-antichymotrypsin in patients with benign prostatic hyperplasia].
Grigor'ev ME; Mazo EB; Chekhonin VP
Urol Nefrol (Mosk); 1998; (4):33-7. PubMed ID: 9727319
[TBL] [Abstract][Full Text] [Related]
2. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
3. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
España F; Martínez M; Royo M; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF
Eur Urol; 1997; 32(3):268-72. PubMed ID: 9358211
[TBL] [Abstract][Full Text] [Related]
4. Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Reiter W; Stieber P; Schmeller N; Nagel D; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4767-70. PubMed ID: 9494604
[TBL] [Abstract][Full Text] [Related]
5. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
van Vuuren SP; Heyns CF; Zarrabi AD
BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
[TBL] [Abstract][Full Text] [Related]
6. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
[TBL] [Abstract][Full Text] [Related]
7. First clinical results with Enzymun-Test for free PSA.
Gilson G; Lamy S; Humbel RL
Anticancer Res; 1997; 17(4B):2861-4. PubMed ID: 9329548
[TBL] [Abstract][Full Text] [Related]
8. [Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"].
Imai K; Yamanaka H; Kubota Y; Miki M; Ito T; Akaza H; Uchida K; Egawa S; Kuriyama M; Watanabe H; Okihara K; Kotake T; Usami M; Arai Y; Maeda H; Sagiyama K; Saito Y; Sakai H; Shida K
Hinyokika Kiyo; 1998 Oct; 44(10):755-63. PubMed ID: 9850846
[TBL] [Abstract][Full Text] [Related]
9. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
10. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
11. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
[TBL] [Abstract][Full Text] [Related]
13. [A clinical analysis of benign prostatic hyperplasia with chronic prostatitis].
Wu XJ; Yang LY; Zhang XZ
Zhonghua Nan Ke Xue; 2008 Jun; 14(6):527-9. PubMed ID: 18649752
[TBL] [Abstract][Full Text] [Related]
14. [Impact of prostatic benign hyperplasia and prostatic inflammation on the increase of prostate specific antigen levels].
Ferrero Doria R; Pérez Flores D; Terrer Artes C; Guzmán Martínez-Valls PL; Morga Egea JP; Tomás Ros M; Rico Galiano JL; Sempere Gutiérrez A; Fontana Compiano LO
Actas Urol Esp; 1997 Feb; 21(2):100-4. PubMed ID: 9214204
[TBL] [Abstract][Full Text] [Related]
15. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
16. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
17. [Concentrations of free form and complex form of prostate-specific antigen in serum of alpha 2 macroglobulin deficient patients with prostatic carcinoma].
Kanoh Y; Jimbo S; Shibuya M; Matsuyama N; Mashiko T; Tanaka T; Egawa S; Ohtani H
Rinsho Byori; 1998 Sep; 46(9):923-9. PubMed ID: 9800478
[TBL] [Abstract][Full Text] [Related]
18. [Clinical features of benign prostatic hyperplasia complicated by chronic prostatitis].
Chang DG; Li GS; Zhang PH; Wu TL; Mei XF; Cao J; Gao P
Zhonghua Nan Ke Xue; 2010 Sep; 16(9):830-3. PubMed ID: 21171270
[TBL] [Abstract][Full Text] [Related]
19. [Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer].
Zenimoto M; Kita M; Arai T; Murayama T; Mori M
Rinsho Byori; 2003 Oct; 51(10):969-73. PubMed ID: 14653195
[TBL] [Abstract][Full Text] [Related]
20. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin.
Lilja H
Urol Clin North Am; 1993 Nov; 20(4):681-6. PubMed ID: 7505976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
